Endo cuts 2012 forecast on poor Opana sales; Hungary's Richter hikes its expectations;

@FiercePharma: Congressional hearings on the meningitis debacle to begin next week. FDA's Hamburg on the sked: Report | Follow @FiercePharma

> Endo Health Solutions ($ENDP) failed to deliver on third-quarter revenue, as lower sales of its pain drug Opana ER fell short; the company cut its 2012 outlook for the second time in two months. Report

> Hungary's Richter raised its 2012 growth forecast to 3%, after previously predicting flat sales for the year; margins are still expected to drop from 2011. Report

> India's Cipla reported strong growth for the first half of its fiscal year, but analysts worry that it may not continue. Report

> AMAG Pharmaceuticals said its partner Takeda has launched its anemia drug Rienso in Europe; it's sold as Feraheme in the U.S. Report

> AFK Sistema may buy a controlling interest in Russia's VeroPharm from the troubled pharmacy chain 36.6. Report

Medical Device News

 @FierceMedDev: After another quarterly slide, Wright Medical is planning to reorganize. Report | Follow @FierceMedDev

 @MarkHFierce: FDA warns the maker of a light therapy product designed to treat fungal meningitis that the product is unapproved. More | Follow @MarkHFierce

 @DamianFierce: Myriad Genetics is raising its full-year guidance after a strong quarter. More | Follow @DamianFierce

> FDA cites Tennessee company for meningitis light therapy device. Item

> St. Jude chases renal denervation market share with new study. Report

Biotech News

 @FierceBiotech: From FierceVaccines.com: PsiOxus lands $2.7M for ovarian cancer vaccine trial. Item | Follow @FierceBiotech

 @JohnCFierce: Buyout Buzz: The most frequently cited takeover targets in biotech. Special Report | Follow @JohnCFierce

 @RyanMFierce: Crowdsourcing kick spurs interest in NIH drug recycling. More | Follow @RyanMFierce

> PCSK9 rivals Amgen and Pfizer angle for AHA spotlight with promising data. Story

> Takeda snaps up CNS drug developer Envoy Therapeutics in $140M deal. News

> Ambit Biosciences finds $50M more from VCs as leukemia therapy advances. Article

Biotech Research News

> Failed AstraZeneca drugs gain second chance with $11M U.K. program. News

> UC Davis team finds new lung cancer Rx target. Article

> 'Abdominal imaging window' lets researchers crack cancer metastasis secrets. Story

> Scientists wield stem cells to undo male infertility inflicted by cancer treatment in monkeys. More

Pharma Manufacturing News

> India's price-setting agency prepares for plant inspections. Story

> Sigma-Aldrich gets foothold in S. Korea with API deal. Article

> German Bayer partners with Russian drug manufacturer. News

And Finally... Daily multivitamins didn't cut men's risk of heart attack in a long-term study. Report

 

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.